Vu, Tam
Vallmitjana, Alexander http://orcid.org/0000-0002-7149-9385
Gu, Joshua
La, Kieu
Xu, Qi http://orcid.org/0000-0003-4124-1364
Flores, Jesus
Zimak, Jan
Shiu, Jessica
Hosohama, Linzi
Wu, Jie
Douglas, Christopher
Waterman, Marian L. http://orcid.org/0000-0003-4823-4968
Ganesan, Anand
Hedde, Per Niklas http://orcid.org/0000-0002-2994-369X
Gratton, Enrico http://orcid.org/0000-0002-6450-7391
Zhao, Weian http://orcid.org/0000-0002-7794-9914
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Cancer Institute (U54CA217378, P30CA062203)
U.S. Department of Health & Human Services | NIH | National Cancer Institute
U.S. Department of Health & Human Services | NIH | National Institute of Arthritis and Musculoskeletal and Skin Diseases (P30AR075047)
U.S. Department of Health & Human Services | NIH | National Institute of General Medical Sciences (R21GM135493, P41GM103540)
U.S. Department of Health & Human Services | NIH | National Institute of General Medical Sciences
Article History
Received: 23 June 2021
Accepted: 15 December 2021
First Online: 10 January 2022
Competing interests
: T.V. and A.V. are now Arvetas Biosciences Inc employees. W.Z. is a cofounder of Velox Biosystems Inc., Amberstone Biosciences Inc., and Arvetas Biosciences Inc. P.N.H. holds a part-time position at Amberstone Biosciences Inc. A.G. is a founder of Alyra therapeutics. The remaining authors declare no competing interests.